Background {#S1}
==========

Cancer, a major killer of human health, constitutes an enormous burden on society in both more and less economically developed countries. According to GLOBOCAN statistics, about 14.1 million new cancer cases were diagnosed and 8.2 million cancer-associated deaths occurred in 2012 all over the world ([@B92]). Cancer is a complex disease. Multiple lines of evidence suggest that numerous risk elements, containing genetic and environmental factors, account for cancer initiation and development, among which the involvement of mis-regulation of non-coding RNAs (ncRNAs) in cancer has aroused extensive attention during the past few decades.

Based on length, ncRNAs can be divided into several subtypes, such as microRNA (miRNA), long non-coding RNA (lncRNA) as well as circular RNA (circRNA). ncRNAs, especially miRNA, have been solely studied until a famous hypothesis, namely competing endogenous RNA (ceRNA) mechanism, which was proposed by the team of [@B81]. ceRNA hypothesis represents a hidden RNA language that messenger RNA (mRNA) can cross talk with lncRNA or circRNA by competitively binding to shared miRNAs, and eventually influence physiological and pathological processes ([@B71]; [@B102]; [@B132]). After the emergence of ceRNA hypothesis, ncRNA-related research has been developed rapidly.

[@B34] introduced a new word "pseudogene" when they discovered a copy of the 5S rRNA gene in Xenopus laevis. The copy with 5′-end truncation and 14-bp mismatches makes it non-functional. From then on, a large number of pseudogenes have been gradually found in a variety of prokaryotes and eukaryotes, including homo species. For a long time, pseudogenes are considered as non-functional "junk genes," "relics of evolution" or "genomic fossil."

In recent years, with the huge advancement of in-deep research, multilayered functions of pseudogene DNAs, RNAs or proteins have been reported in various types of human cancer ([@B112]), among which pseudogene-derived RNA transcripts are the most investigated. Pseudogene-expressed RNAs are key components of lncRNAs. Similar as common lncRNAs, pseudogene-derived lncRNAs can also function as critical modulators in initiation and development of human cancer by ceRNA mechanism *via* sponging miRNAs, which is supported by increasing findings. Therefore, in this work, we highlight recent findings regarding the expression, function and miRNA sponging mechanism of pseudogene-derived lncRNAs in diverse types of human cancer.

Origination and Classification of Pseudogenes and Pseudogene-Derived lncRNAs {#S2}
============================================================================

Based on the origination form from its ancestral gene, pseudogenes can be classified into three types: (1) processed pseudogenes or retrotransposed pseudogenes deriving from retrotransposition of processed mRNA back into the genome; (2) unprocessed pseudogenes or duplicated pseudogenes deriving from unfaithful gene duplications; and (3) unitary pseudogenes deriving from gene mutations ([@B112]). lncRNAs are divided into several categories according to genomic organization and relation to coding genes, such as long intergenic non-coding RNAs, antisense RNAs, sense overlapping RNAs, sense intronic RNAs, enhancer RNAs as well as pseudogene-expressed lncRNAs ([@B25]). Although only few of pseudogenes can be transcribed, all the three types of pseudogenes may transcribe and are called transcribed pseudogenes or pseudogene-derived transcripts. However, compared with other members of lncRNAs, transcribed pseudogenes-derived lncRNAs have not been paid attention previously. Recent studies have demonstrated that transcribed pseudogene-derived lncRNAs play important roles in multiple biological processes, such as cell proliferation, cell cycle, cell migration and cell death ([@B43]; [@B70]; [@B94]).

Competing Endogenous RNA Mechanism of Pseudogene-Derived lncRNA {#S3}
===============================================================

Previous evidences have suggested that pseudogene-expressed RNAs could function as antisense RNAs or endo-siRNAs ([@B40]; [@B105]). Besides, recent studies have also found that pseudogene-expressed RNAs serve as sponges of miRNAs and thus exert biological roles. To better understand the miRNA sponge mechanism of pseudogene-derived lncRNAs in cancer, competing endogenous RNA (ceRNA) mechanism proposed by [@B81] should be introduced. In this hypothesis, messenger RNA, lncRNA and circRNA can "talk" to each other by binding to shared miRNAs using miRNA response elements (MREs). Dysregulation of lncRNAs, pseudogenes and circRNAs leads to alteration of abundance of miRNAs, thus affecting their inhibition of downstream target expression. This mechanism also applies to pseudogene-derived transcripts. To date, ceRNA mechanism is validated to participate in initiation and progression of human cancer when its dysregulated ([@B78]; [@B117]). Based on ceRNA mechanism, researchers and scholars have discovered a variety of potential cancer-associated pseudogenes using *in silico* analysis. For example, [@B107] identified three pseudogene-involved ceRNA triples in lung adenocarcinoma, including NKAPP1-miR-21-5p-PRDM11, MSTO2P-miR-29c-3p-EZH2 and RPLP0P2-miR-29c-3p-EZH2; [@B35] screened several prostate cancer-related pseudogenes by establishing pseudogene-miRNA-gene triple ceRNA regulatory network. Lab experiments also confirmed the involvement of pseudogene-mediated ceRNA mechanism in cancer development. For instance, HMGA1 pseudogenes, HMGA1P6 and HMGA1P7, were reported to serve as candidate proto-oncogenic ceRNAs ([@B19]); HMGA1P7 was also found to sustain overexpression of H19 and lgf2 by acting as decoy for miR-15, miR-16, miR-214, and miR-761 ([@B14]). [@B38] suggested that BRAF pseudogenes BRAF-RS1 and BRAFP1 functioned as ceRNAs to elevate BRAF expression and activate MAPK signaling, thereby eliciting their roles in lymphoma.

Expression and Functions of Pseudogene-Derived lncRNAs in Human Cancer {#S4}
======================================================================

Dysregulation of pseudogenes and their transcripts has been implicated into initiation and/or progression of human disorders, including cancer. Among pseudogene-derived lncRNAs, some act as tumor promotors, facilitating cancer development, whereas the other function as tumor suppressors, inhibiting cancer progression. In this part, we summarized the upregulated oncogenic pseudogene-derived lncRNAs and downregulated tumor suppressive pseudogene-derived lncRNAs in diverse types of human cancer ([Figure 1](#F1){ref-type="fig"}).

![Overview of reported upregulated and downregulated pseudogene-derived lncRNAs in diverse types of human cancer.](fcell-08-00085-g001){#F1}

Upregulated Oncogenic Pseudogene-Derived lncRNAs {#S5}
================================================

Liver Cancer {#S5.SS1}
------------

As is known to all, hepatitis B virus (HBV) infection is closely linked to occurrence of hepatocellular carcinoma (HCC). PCNAP1 was reported to boost HBV replication, thus enhancing tumor growth of HCC ([@B21]). lncRNA PTTG3P was markedly upregulated in HCC samples compared with normal samples and its overexpression promoted growth and metastasis of HCC by increasing its cognate gene PTTG1 and activating PI3K/AKT signaling pathway ([@B31]). p53 signaling is a widely acknowledged tumor suppressive pathway in multiple human cancers, including HCC ([@B66]). PDIA3P1, upregulated in HCC tissues compared with paired normal adjacent tissues, could increase proliferation, migration and invasion, and decrease apoptosis of HCC by suppressing p53 signaling pathway ([@B39]). UBE2CP3 was significantly upregulated in HCC and was discovered to function as an oncogene by increasing tumor metastasis through inducing epithelial-mesenchymal transition ([@B7]). [@B53] also confirmed the oncogenic role of UBE2CP3 in HCC, facilitating angiogenesis *via* activation of ERK1/2/HIF-1alpha/VEGFA signaling. Another highly expressed pseudogene-derived lncRNA, PDPK2P, also exhibited these oncogenic effects on HCC by PDK1/AKT/caspase 3 signaling pathway ([@B72]). OCT4-pg4, acting as a natural sponging of miR-145 to upregulating OCT4, exerted an oncogenic role in hepatocarcinogenesis by promoting growth ([@B96]). HCC is notorious for its high aggressiveness and easy to relapse. A recent study conducted by the team of Wang Q demonstrated that ANXA2P2 was highly expressed in HCC and promoted an aggressive phenotype of HCC ([@B99]). And [@B98] confirmed that RACGAP1P facilitated early recurrence of HCC by activating RACGAP1/Rho/ERK signaling axis. Dysregulation of pseudogenes and their transcripts accounts for the development of chemo-resistance and radio-resistance of HCC which greatly reduces the efficacy of chemotherapy and radiotherapy. For example, [@B113] suggested that PDIAP3 caused doxorubicin resistance of HCC by targeting miR-125/124-TRAF6/NF-KB signaling; [@B143] found that knockdown of SUMO1P3 markedly enhanced radio-sensitivity in HCC.

Breast Cancer {#S5.SS2}
-------------

CYP4Z2P, an oncogenic pseudogene of CYP4Z1, has been widely investigated in breast cancer. The 3′UTR of CYP4Z2P was found to promote angiogenesis of breast cancer ([@B139], [@B138]). The ceRNA network of CYP4Z2P and its parental gene CYP4Z1 exerted an anti-apoptotic function in breast cancer ([@B44]). Tamoxifen is an effective therapy for estrogen receptor (ER)-positive breast cancer. [@B140] discovered that the ceRNA network of CYP4Z2P and CYP4Z1 conferred tamoxifen resistance of breast cancer. The ceRNA network, activated by transcriptional factor six2, was also responsible for maintaining the stemness of breast cancer ([@B137]). In addition to CYP4Z2P, some pseudogene-derived lncRNAs were also found to function as oncogenes in breast cancer. For example, [@B55] confirmed that SUMO1P3 promoted proliferation, migration and invasion of breast cancer; [@B4] found that CRYbetaB2P1 was upregulated in breast cancer and facilitated progression of breast cancer by increasing CRYbetaB2 expression; and [@B100] demonstrated that FTH1P3 led to paclitaxel resistance of breast cancer. PTTG3P was markedly upregulated in breast cancer samples compared with normal controls and its upregulated linked to poor prognosis of patients with breast cancer ([@B58]).

Gastric Cancer {#S5.SS3}
--------------

NANOGP8 expression was significantly elevated in gastric cancer and knockdown of NANOGP8 resulted in decreased proliferation and promoted apoptosis of gastric cancer cells ([@B46]). [@B65] also suggested that NANOGP8 was a positive regulator of gastric cancer stem cells, associated with epithelial-mesenchymal transition, stemness, cancer stem cell markers as well as Wnt signaling pathway. DUXAP8, a 2107 nt RNA derived from pseudogene, was obviously upregulated in gastric cancer and significantly associated with greater tumor size, advanced clinical stage and lymphatic metastasis ([@B64]). Overexpression of DUXAP8 promoted cell proliferation and migration of gastric cancer by epigenetically inhibiting PLEKHO1 expression. Another DUXA-associated pseudogene, DUXAP10, also exerted its oncogenic roles in gastric cancer by transcriptionally repressing LATS1 expression and maintaining the stability of beta-catenin mRNA ([@B115]). POU5F1B, a processed pseudogene highly homologous to OCT4, was frequently amplified in gastric cancer cell lines and clinical specimens when compared with their corresponding controls ([@B29]). Furthermore, after POU5F1B overexpression in gastric cancer, a variety of growth factors were induced and an aggressive phenotype was exhibited. [@B69] showed that MSTO2P was markedly associated with lymphatic metastasis and distal metastasis and promoted growth, colony formation, migration and invasion of gastric cancer. High expression PTTG3P linked to large tumor size, increased tumor invasiveness and served as an unfavorable prognostic biomarker ([@B109]). Besides, the abilities of gastric cancer proliferation and invasion were enhanced after ectopic expression of PTTG3P. [@B103] found that DUSP5P1, directly induced by C8orf76, fueled gastric tumorigenicity and metastasis by activating MAPK signaling pathway. SUMO1P3 was significantly upregulated in gastric cancer and correlated with tumor size, differentiation, lymphatic metastasis and invasion ([@B67]). ROC curve analysis also indicated that high expression level of SUMO1P3 might be a potential diagnostic biomarker for gastric cancer. However, its functions in gastric cancer remain unclear and need to be further investigated.

Colorectal Cancer {#S5.SS4}
-----------------

High SUMO1P3 level was reported to be associated with advanced histological stages, metastasis, angiogenesis and poor prognosis of colon cancer patients ([@B130]). Inhibition of SUMO1P3 repressed proliferation, migration, invasion and pro-angiogenesis of colon cancer cells *in vitro*, and reduced growth, liver metastasis and vascularization of colon cancer *in vivo* by decreasing cyclin D1, vimentin and VEGFA but increasing *E*-cadherin expression. FLT1P1markedly promoted cell proliferation *in vitro* and xenograft tumor growth *in vivo* ([@B122]). TPTE2P1 levels in colorectal cancer tissues were higher than that in adjacent normal tissues, and its upregulation was markedly associated with poor patients' survival ([@B13]). The authors also indicated that silencing expression of TPTE2P1 resulted in cell cycle arrest at S phase and caused cell apoptosis in colorectal cancer. Moreover, the tumor suppressive effects of TPTE2P1 on colorectal cancer was observed in the *in vivo* experiment. DUXAP8 was remarkably overexpressed in colorectal cancer and DUXAP8 knockdown led to inhibited proliferation, migration and invasion and enhanced apoptosis ([@B17]). [@B52] suggested that another DUXA-associated pseudogene-derived lncRNA, DUXAP10, was also evidently upregulated in colorectal cancer and positively correlated with advanced pathological stages, larger tumor sizes and lymph node metastasis. DUXAP10 promoted cell proliferation and cell cycle progression and blocked cell apoptosis by epigenetically silencing expression of p21 and PTEN.

Lung Cancer {#S5.SS5}
-----------

SUMO1P3 expression was markedly increased in non-small cell lung cancer tissues and cells compared with corresponding normal controls and in metastatic lymph node specimens in comparison to primary tumor tissue specimens ([@B133]). The authors also confirmed high SUMO1P3 expression was correlated with late clinical stage, lymph node metastasis, distant metastasis and poor differentiated degree. Moreover, SUMO1P3 enhanced cell migration and invasion of non-small cell lung cancer. [@B86] reported that DUXAP8, upregulated in non-small cell lung cancer and an unfavorable prognostic biomarker, significantly facilitated cell growth, migration and invasion, and impaired apoptosis both *in vitro* and *in vivo* by epigenetically silencing EGR1 and RHOB. DUXAP10 expression was identified to be overexpressed in non-small cell lung cancer tissues and cell lines and its upregulation was correlated with poor prognosis of patients with non-small cell lung cancer ([@B106]). Functional and mechanistic experiments suggested that DUXAP10 exerted oncogenic roles in non-small cell lung cancer by binding to LSD1 and epigenetic silencing expression of LATS2 and RRAD.

Brain Cancer {#S5.SS6}
------------

Glioma and glioblastoma are two main types of brain cancer. Pseudogene-derived lncRNAs are found to facilitate development and progression of glioma and glioblastoma. For example, [@B134] FTH1P3 was reported to be upregulated in glioma tissues and high-grade glioma tissues when compared with normal brain tissues and low-grade glioma tissues, respectively. Overexpression of FTH1P3 enhanced glioma cell proliferation and inhibited apoptosis by regulating miR-224-5p/TPD52 pathway. Another study by [@B114] demonstrated that LGMNP1 was significantly increased in glioblastoma cells after radiation and its overexpression conferred radio-therapy resistance in glioblastoma by reducing DNA damage and apoptotic population.

Endometrial Cancer {#S5.SS7}
------------------

The expression level of OGFRP1 was significantly upregulated in endometrial cancer ([@B62]). [@B62] also experimentally confirmed that knockdown of OGFRP1 suppressed the malignant behaviors of endometrial cancer, including suppressed cell viability, enhanced cell apoptosis and inhibited cell migration and invasion. OCT4-pg5 was found to be aberrantly activated in endometrial cancer samples compared with benign endometrium samples, and increased expression of OCT4-pg5 enhanced proliferation by promoting OCT4/PI3K/AKT/CCND1 signaling ([@B3]).

Esophageal Squamous Cell Carcinoma {#S5.SS8}
----------------------------------

[@B20] reported that PHBP1, markedly upregulated in esophageal squamous cell carcinoma and positively correlated with clinical advanced stage, facilitated proliferation, colony formation and xenograft tumor growth *in vitro* and *in vivo* by inducing cell cycle arrest. PTTG3P expression was found to increase in esophageal squamous cell carcinoma tissues and cell lines ([@B135]). Enhanced expression of PTTG3P greatly stimulated migration and invasion of esophageal squamous cell carcinoma through upregulating expression levels of PTTG1 and PTTG2 ([@B135]). [@B119] demonstrated that FTH1P3 was notably upregulated in esophageal squamous cell carcinoma and knockdown of FTH1P3 significantly inhibited proliferation, migration and invasion of esophageal squamous cell carcinoma cells by regulating SP1/NF-kB signaling. The study conducted [@B104] certified an obvious increased expression of DUXAP10 in esophageal squamous cell carcinoma. They also showed that DUXAP10 was positively correlated with poor prognosis and epigenetically silenced p21 by recruiting EZH2 to the promoter of p21, thereby promoting cell proliferation and metastasis.

Renal Cell Carcinoma {#S5.SS9}
--------------------

[@B11] demonstrated that DUXAP8 and DUXAP9 were significantly upregulated in renal cell carcinoma, promoted tumor growth and served as two unfavorable prognostic biomarkers for patients with renal cell carcinoma. DUXAP8 was also discovered to enhance progression of renal cell carcinoma ([@B32]). Androgen receptor plays key roles in development of renal cell carcinoma. [@B95] found androgen receptor could decrease the expression of ASS1P3, a pseudogene of ASS1, and thus facilitate cell growth of renal cell carcinoma.

Pancreatic Cancer {#S5.SS10}
-----------------

The oncogenic function of SUMO1P3 in the development of pancreatic cancer was reported by [@B91]. They found that SUMO1P3 expression was markedly elevated in pancreatic cancer tissues when compared with normal controls. Functional experiments revealed the enhanced effect of SUMO1P3 on proliferation, migration and invasion of pancreatic cancer. By epigenetically silencing CDKN1A an KLF2, DUXAP8, upregulated in pancreatic cancer, promoted growth of pancreatic cancer ([@B51]). The team of [@B50] demonstrated that DUXAP10 expression was higher in renal cell carcinoma patients with an advanced TNM stage and positive lymph node metastasis. They also confirmed that knockdown of DUXAP10 could result in inhibited proliferation, migration, invasion and enhanced apoptosis in renal cell carcinoma through interacting with RNA-binding proteins, EZH2 and LSD1. Depletion of ZFP91P significantly decreased cell proliferation and migration capacities of pancreatic cancer by altering beta-catenin and vimentin expression ([@B33]).

Other Types of Cancer {#S5.SS11}
---------------------

SUMO1P3 was increased in bladder cancer and its high expression predicted poor prognosis of patients with bladder cancer ([@B127]). Furthermore, after knockdown of SUMO1P3, bladder cancer exhibited cell proliferation and migration inhibition and apoptosis induction ([@B127]).

PTTG3P, a pseudogene of PTTG1 which is upregulated in many types of cancer, was found to promote cervical cancer growth and metastasis by enhancing PTTG1 expression ([@B27]). Recently, [@B57] showed that RSU1P2 was increased in cervical cancer and boosted the malignant phenotype of cervical cancer. POU5F1B was also reported to be upregulated in cervical cancer tissues and cell lines by [@B124]. The authors confirmed that interference with expression of POU5F1B significantly suppressed cell proliferation, migration and invasion, and induced apoptosis in cervical cancer ([@B124]).

Gallbladder is a rare malignant tumor with poor prognosis all over the world. Two pseudogene-derived lncRNAs, TPTE2P1 and Loc344887, have been documented to play oncogenic roles in development of gallbladder cancer ([@B61]; [@B111]). Depletion of TPTE2P1 significantly blocked epithelial-mesenchymal transition, migration and invasion of gallbladder cancer ([@B61]). Loc344887 was elevated in gallbladder cancer, was positively associated with larger tumor size, and facilitated cell proliferation, cell cycle progression, migration and invasion ([@B111]).

[@B93] suggested that NANOGP8 overexpression remarkably increased cell proliferation whereas its inhibition suppressed the proliferation in human gastrointestinal cancer cells.

[@B126] confirmed FTH1P3 was significantly upregulated in laryngeal squamous cell cancer and positively linked to the poor differentiation, high T classification, positive lymph node metastasis and advanced clinical stage. The authors also demonstrated that FTH1P3 overexpression resulted in enhancement of cell proliferation, migration and invasion and inhibition of cell apoptosis in laryngeal squamous cell cancer ([@B126]).

FTH1P3 expression was also increased in uveal melanoma and elevated expression of FTH1P3 promoted cell proliferation, cell cycle and migration of uveal melanoma ([@B2]).

The group of Zang (2017) suggested that FTH1P3 facilitated cell proliferation and colony formation in oral squamous cell carcinoma by upregulating the expression of fizzled 5.

[@B121] demonstrated that PDIA3P was highly expressed in multiple myeloma, was correlated with poor prognosis of patients with multiple myeloma, and induced growth and drug resistance of multiple myeloma.

Two pseudogene-derived lncRNAs, HMGA1P6 and HMGA1P7, contributed to increase its cognate gene HMGA1 level in human pituitary tumor and then to pituitary tumorigenesis ([@B18]).

Downregulated Tumor Suppressive Pseudogene-Derived lncRNAs {#S6}
==========================================================

Liver Cancer {#S6.SS1}
------------

psiPPM1K, a retrotranscript pseudogene, was significantly reduced in HCC surgical specimens ([@B9]). Two endo-siRNAs originated from psiPPM1K are found to inhibit oncogenic cell growth of HCC. Low expression of lncRNA PTENP1 in HCC has been reported ([@B10]). A similar result was also identified by another study conducted by [@B77]. They found that PTENP1 suppress HCC migration and invasion through enhancing PTEN signaling by interacting with miR-193a-3p. INTS6P1 upregulated its cognate gene INTS6 through competitively binding to miR-17-5p, thereby functioning its tumor suppressive roles in HCC ([@B74]). [@B101] indicated that AOC4P inhibited metastasis of HCC by enhancing degradation of vimentin and suppressing epithelial-mesenchymal transition. MT1DP, directly inhibited by YAP and Runx2, resulted in reduced cell proliferation and colony formation in soft agar, but increased apoptosis in liver cancers ([@B125]).

Breast Cancer {#S6.SS2}
-------------

PTENP1 was reported as a tumor suppressor in development and progression of breast cancer. For instance, a recent study conducted by [@B88] showed that PTENP1 suppressed proliferation and migration of breast cancer by inhibiting AKT and MAPK signaling pathways; another study performed by [@B23] demonstrated that PETNP1 increased expression of PTEN, thus mediating proliferation, invasion and drug resistance of breast cancer by activation of PI3K/AKT pathway. Connnexin 43 pseudogene, PsiCx43, increased sensitivity to cytotoxic chemotherapy of breast cancer ([@B6]). SEPW1P RNA was also validated to participate in PIWI-interacting RNA-36712-mediating suppression of breast cancer progression ([@B87]).

Gastric Cancer {#S6.SS3}
--------------

PTENP1 has been demonstrated to function as a tumor suppressor in several cancer cells, containing gastric cancer. For example, [@B26] found that PTENP1 was frequently downregulated in gastric cancer, and suppressed proliferation, migration, invasion and promoted apoptosis of gastric cancer through increasing PTEN expression; [@B131] also confirmed the tumor suppressive roles of PTENP1 in gastric cancer by decoying miR-106b and miR-93 and thus upregulating PTEN expression. Apart from PTENP1, some pseudogene-derived lncRNAs were also demonstrated to be downregulated in gastric cancer and play tumor suppressive roles in gastric cancer progression. SFTA1P, which is 693 nt long, was obviously decreased in gastric cancer tissues compared with the adjacent normal tissues ([@B63]). Increased expression of SFTA1P suppressed proliferation, migration and invasion of gastric cancer by partially inhibiting p53 signaling. Downregulation of KRT19P3 in gastric cancer cells and tissues was confirmed by [@B136]. Functional experiments suggested that enforced expression of KRT19P3 significantly blocked cell proliferation and metastasis both *in vitro* and *in vivo*. KRT19P3-mediated enhancement of COPS7A protein stability accounted for its roles in suppressing gastric cancer.

Colorectal Cancer {#S6.SS4}
-----------------

Increasing evidence have supported the involvement of pseudogene-derived lncRNAs in the suppression of pathogenesis of cancer, including colorectal cancer. For example, [@B12] confirmed that CTNNAP1 was significantly downregulated in colorectal cancer. The degree of CTNNAP1 dysregulation was markedly correlated with TNM stage. Furthermore, overexpression of CTNNAP1 could suppressed cell proliferation and tumor growth *in vitro* and *in vivo via* induction of G0/G1 cell cycle arrest. Sulforaphane, an anticancer agent, exerts its effects partially by inducing Nrf2-dependent signaling. The investigation performed by the group of Johnson G demonstrated that silencing of NMRAL2P could protect against sulforaphane-mediated inhibition of cell growth, colony formation and migration in colon cancer ([@B36]).

Lung Cancer {#S6.SS5}
-----------

By combination of bioinformatics analysis and experimental validation, [@B129] suggested that SFTA1P was downregulated in both lung adenocarcinoma and lung squamous cell carcinoma and inhibited tumor growth, migration and invasion. The downregulation of SFTA1P in lung squamous cell carcinoma was also reported by the team of [@B47]. They found elevated SFTA1P induced apoptosis and enhanced the sensitivity to cisplatin of lung squamous cell carcinoma. Intriguingly, low expression of SFTA1P was only correlated with lung adenocarcinoma patients' poor prognosis but not with lung squamous cell carcinoma patients' prognosis ([@B129]). Besides, [@B83] confirmed that CHIAP2 expression was markedly decreased in lung adenocarcinoma. After upregulation of CHIAP2, the impaired proliferation and invasion of lung adenocarcinoma were observed.

Brain Cancer {#S6.SS6}
------------

PTENP1 is a tumor suppressive pseudogene-derived lncRNA reported in multiple types of cancer as well as brain glioma. [@B30] reported that expression of PTENP1 was decreased in glioma tissues compared with normal brain tissues and forced expression of PTENP1 inhibited cell proliferation and migration *in vitro* by inducing p21 expression and blocking p38 signaling pathway. In addition, [@B116] first identified HERC2P2 as a potential tumor suppressor in glioma by constructing a ceRNA network based on the Chinese Glioma Genome Atlas database. Subsequently, they also validated that HERC2P2 overexpression attenuated migration and colony formation abilities of glioma *in vitro* and inhibited glioma xenograft growth *in vivo*.

Esophageal Squamous Cell Carcinoma {#S6.SS7}
----------------------------------

The tumor suppressive role of PTENP1 in esophageal squamous cell carcinoma was reported by [@B24]. They found a downregulated expression of PTENP1 in esophageal squamous cell carcinoma compared with the corresponding adjacent normal tissues and overexpression of PTENP1 inhibited tumor proliferation (esophageal squamous cell carcinoma). [@B54] suggested TUSC2P was decreased in esophageal squamous cell carcinoma and its downregulation linked to unfavorable prognosis of patients with esophageal squamous cell carcinoma. The inhibitory effects of TUSC2P on proliferation and invasion of esophageal squamous cell carcinoma were also experimentally validated in the study ([@B54]). TUSC2P-mediated upregulation of TUSC2 was partially responsible for the tumor suppressive roles of TUSC2P in esophageal squamous cell carcinoma ([@B54]).

Other Types of Cancer {#S6.SS8}
---------------------

PTENP1 was downregulated in head and neck squamous cell carcinoma and its low expression correlated with poor patients' prognosis ([@B56]). Upregulation of PTENP1 led to inhibited proliferation, colony formation and migration *in vitro* and suppressed growth *in vivo* in head and neck squamous cell carcinoma ([@B56]).

PTENP1 was reported to act as a tumor suppressor in clear-cell renal cell carcinoma by [@B123]. They found that PTENP1 was downregulated in clear-cell renal cell carcinoma and overexpression of PTENP1 reduced cell proliferation, migration, invasion *in vitro* and tumor growth and metastasis *in vivo* ([@B123]).

[@B22] suggested that PTENP1, protecting PTEN transcripts from being inhibited by miR-21, suppressed proliferation and colony formation of oral squamous cell carcinoma.

ceRNA Mechanism Contributes to the Roles of Pseudogene-Derived lncRNAs in Human Cancer {#S7}
======================================================================================

Over the past decades, pseudogenes have been documented to play crucial roles in diverse cancer types in DNA, RNA and protein levels ([@B73]; [@B112]). Considering study progresses, this work mainly reviewed the miRNA sponging function of pseudogene-derived lncRNAs in human cancer ([Table 1](#T1){ref-type="table"}).

###### 

Summary of dysregulated pseudogenes and its molecular mechanism in diverse types of cancer.

  **Name**              **Cancer type**                        **Function**                                                                                              **Binding miRNAs**                                                            **Pathway**                                          **References**
  --------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------- ----------------
  WTAPP1                Multiple cancer                        Promote migration and angiogenesis of endothelial progenitor cells                                        miR-3120                                                                      Akt/PI3K                                             [@B105]
  FLT1P1                Colorectal cancer                      Promote proliferation and growth                                                                          miR-520a                                                                      VEGFR1, VEGF-A                                       [@B122]
  TUSC2P                Esophageal squamous cell carcinoma     Inhibit proliferation and invasion and promote apoptosis                                                  miR-17-5p/miR-520a-3p/miR-608/miR-661                                                                                              [@B54]
                        Multiple cancer                        Inhibit proliferation, survival, migration, invasion and colony formation and increases cell death        miR-17/miR-93/miR-299-3p/miR-520a/miR-608/miR-661                                                                                  [@B40]
  SUM01P3               Non-small cell lung cancer             Promote cell migration and invasion                                                                       miR-136                                                                                                                            [@B133]
  SEPW1P                Breast cancer                          Promote cell proliferation, invasion and migration and confer chemoresistance                             miR-7/miR-324                                                                 p53 signaling                                        [@B87]
  RSU1P2                Cervical cancer                        Promote tumor role                                                                                        let-7a                                                                        IGF1R, N-myc and EphA4                               [@B57]
  RP11-564D11.3         Hepatocellular carcinoma               Correlate with poor overall survival of patients                                                          miR-200b-3p/miR-200a-3p/miR-429/miR-101-3p/miR-9-5p/miR-200c-3p/miR-141-3p    VEGFA                                                [@B105]
  RP11-424C20.2         Hepatocellular carcinoma and thymoma   Correlate with immune infiltration                                                                        miR-378a-3p                                                                   UHRF1, IFN-gamma-mediated CLTA-4 and PD-L1 pathway   [@B105]
  RACGAP1P              Hepatocellular carcinoma               Promote cell growth and migration                                                                         miR-15-5p                                                                     RACGAP1/Rho/ERK signaling axis                       [@B105]
  PTTG3P                Breast Cancer                          Correlate with poor prognosis                                                                             miR-129-5p/miR-376c-3p/miR-383-5p                                                                                                  [@B58]
                        Hepatocellular carcinoma               Promote cell proliferation, migration and invasion, and suppress cell apoptosis                           miR-383                                                                       CCND1/PARP2 axis and PI3K/Akt signaling              [@B40]
  PTNEP1                Breast Cancer                          Inhibit tumor progression                                                                                 miR-26a                                                                       PTEN, AKT/mTOR signaling                             [@B1]
                        Hepatocellular carcinoma               Inhibit cell proliferation, migration, invasion as well as induce autophagy and apoptosis                 miR-17/miR-19b/miR-20a                                                        PI3K/AKT pathway                                     [@B10]
                        Oral squamous cell carcinoma           Inhibit proliferation                                                                                     miR-21                                                                        PTEN                                                 [@B22]
                        Esophageal squamous cell               Inhibit growth and correlate with prognosis                                                               miR-17-5p                                                                     SOCS6                                                [@B24]
                        Breast cancer                          Suppress cell proliferation, migration and invasion and promote cell apoptosis                            miR-19b                                                                       p53 signaling, p-AKT                                 [@B48]
                        Breast Cancer                          Inhibits cell proliferation and migration                                                                 miR-19b                                                                       PI3k/Akt pathway                                     [@B84]
                        Multiple cancer                        Glycogen synthesis                                                                                        miR-499-5p                                                                    Insulin signaling                                    [@B97]
                        Clear-cell renal cell carcinoma        Suppress cancer progression                                                                               miR-21                                                                                                                             [@B123]
                        Gastric cancer                         Tumor suppressive role                                                                                    miR-106b/miR-93                                                                                                                    [@B131]
                        Bladder cancer                         Suppress cancer progression                                                                               miR-17                                                                                                                             [@B141]
  PDIA3P1               Hepatocellular carcinoma               Confer chemoresistance                                                                                    miR-125a/miR-125b/miR-124                                                     TRAF6 and NF-kB signaling                            [@B113]
  OCT4-pg5              Endometrial carcinoma                  Promote proliferation                                                                                     miR-145                                                                       OCT4/PI3K/AKT/cyclin D1 signaling                    [@B3]
  OCT4-pg4              Hepatocellular carcinoma               Promote growth and tumorigenicity                                                                         miR-145                                                                       OCT4                                                 [@B96]
  MSTO2P1               Gastric cancer                         Promote the proliferation and colony formation                                                            miR-335                                                                                                                            [@B48]
  INTS6P1               Hepatocellular carcinoma               Suppress cancer progression                                                                               miR-17-5p                                                                     INTS6                                                [@B74]
  HMGA1P6 and HMGA1P7   Breast cancer                          Promote cancer progression                                                                                miR-16                                                                        H19 and IGF2                                         [@B14]
                        Multiple cancer                        Correlate with advanced cancer stage and poor prognosis                                                   miR-483/miR-675                                                               Egr1                                                 [@B15]
                        Thyroid carcinoma                      Promote tumor role                                                                                        miR-15/miR-16/miR-214/miR-761                                                 HMGA1                                                [@B19]
  FTHIP3                Uveal melanoma                         Promote uveal melanoma cell proliferation, cell cycle and migration.                                      miR-224-5p                                                                                                                         [@B2]
                        Prostate cancer                        Promote prostate cancer progression                                                                       miR-638                                                                                                                            [@B8]
                        Breast cancer                          Increase the 50% inhibitory concentration value of paclitaxel and block cell cycle arrest at G2/M phase   miR-206                                                                       ABCB1                                                [@B104]a
                        Oral squamous cell carcinoma           Facilitate cell proliferation and colony formation                                                        miR-224-5p                                                                    Fizzled 5                                            [@B128]
                        Glioma                                 Promote glioma cell proliferation and inhibited apoptosis.                                                miR-224-5p                                                                    TPD52                                                [@B134]
  FOXO3P                Breast cancer                          Suppress tumor growth and cancer cell proliferation and survival.                                         miR-22/miR-136\*/miR-138/miR-149\*/miR-433/miR-762/miR-3614-5p/miR-3622b-5p   FOXO3                                                [@B120]
  DUXAP8 and DUXAP9     Renal cell carcinoma                   promote growth of renal cell carcinoma                                                                    miR-29c-3p                                                                    COL1A1, COL1A2                                       [@B11]
                        Colorectal cancer                      Promote cell proliferation, migration and invasion, and suppress apoptosis                                miR-577                                                                       STAT3/DUXAP8/miR-577/RAB14                           [@B17]
                        Renal Cell Carcinoma                   Enhances Renal Cell Carcinoma Progression                                                                 miR-126                                                                                                                            [@B32]
  CYP4Z2P               Breast cancer                          Inhibit cell apoptosis                                                                                    miR−125a−3p                                                                   AKT and ERK signaling pathways                       [@B44]
                        Breast cancer                          Promote angiogenesis                                                                                      miR-211/miR-125a-3p/miR-197/miR-1226/miR-204                                  Phosphorylation of ERK1/2 and PI3K/Akt               [@B138]
                        Breast cancer                          Render tamoxifen resistance                                                                               miR-125a-3p                                                                   CDK3-depended ERalpha activity                       [@B140]
  CYP2A7P               Liver cancer                                                                                                                                     miR-126                                                                       CYP2A6                                               [@B68]
  CHIAP2                Lung adenocarcinoma                    Inhibit proliferation and invasion                                                                        miR-3614-5p/miR-873-3p                                                        Wnt pathway                                          [@B83]
  ASSIP3                Renal cell carcinoma                   Promote cell proliferation                                                                                miR-34a-5p                                                                    ASS1P3/miR-34a-5p/ASS1 signaling                     [@B95]

PTENP1 {#S7.SS1}
------

PTENP1 functions as a ceRNA and suppress tumor progression in multi-cancers, including breast cancer, HCC, oral squamous cell carcinoma, esophageal squamous cell carcinoma, clear-cell renal cell carcinoma, gastric cancer and bladder cancer. In breast cancer, PTENP1 was found to stimulates expression of PTEN transcript and inhibits cell proliferation and migration through decoying miR-19b ([@B48]; [@B84]). Further, leads to p53 upregulation and p-AKT downregulation. In HCC, long non-coding RNA PTENP1 *via* its ceRNA interaction with miR-17, miR-19b and miR-20a, and finally suppressed cell growth through inhibited oncogenic PI3K/AKT pathway ([@B10]). Additionally, PTENP1 could mediated miR-21 expression and decreased the proliferation ability of oral squamous cell carcinoma and clear-cell renal cell carcinoma ([@B123]; [@B22]). Meanwhile, PTENP1 could suppress bladder cancer progression by regulating miR-17 as well as esophageal squamous cell carcinoma ([@B24]; [@B141]). What's more, PTENP1 functions to modulate PTEN expression by sponging miR-93 and miR-106b, plays a tumor suppressive role in gastric cancer ([@B131]). Not only in cancer, PTEN also contributing to insulin resistance through binding miR-499-5p directly ([@B97]).

FTH1P3 {#S7.SS2}
------

Increasing evidence has demonstrated that FTH1P3 functions as a ceRNA and participates in tumor initiation and development. For example, FTH1P3 facilitated progression of glioma ([@B134]), uveal melanoma ([@B2]), and oral squamous cell carcinoma ([@B128]). Furthermore, FTH1P3 induced paclitaxel resistance by regulating miR-206/ABCB1 axis in breast cancer ([@B100]). [@B8] also suggested a FTH1 gene: pseudogene: microRNA modulated tumorigenesis in prostate cancer.

FLT1P1 {#S7.SS3}
------

FLT1 encodes a member of the vascular endothelial growth factor receptor family. FLT1P1 is a bidirectionally transcribed pseudogene of FLT1. [@B122] confirmed that FLT1P1 antisense transcript suppressed VEGFA by interaction with miR-520a and inhibited tumor cell proliferation and xenograft tumor growth.

CYP4Z2P {#S7.SS4}
-------

CYP4Z2P and CYP4Z1 promoted angiogenesis of breast cancer by commonly targeting miR-211, miR-197, miR-1226, miR-125a, and miR-204 ([@B138]). Moreover, the ceRNA network between CYP4Z1 and CYP4Z2P led to progression of breast cancer, including suppressed apoptosis ([@B44]) and induced tamoxifen resistance ([@B140]).

DUXAP8 and DUXAP9 {#S7.SS5}
-----------------

To date, two DUXA-associated pseudogene-derived lncRNAs, DUXAP8 and DUXAP9, have been discovered to act as ceRNAs to enhance cancer development. For example, [@B11] demonstrated that DUXAP8 and DUXAP9 enhanced growth of renal cell carcinoma by binding to miR-29c-3p and leading to upregulation of COL1A1 and COL1A2; [@B32] suggested that DUXAP8 facilitated progression of renal cell carcinoma by sponging miR-126. DUXAP8, upregulated by STAT3, also fueled migration and invasion of colorectal cancer by functioning as a ceRNA for miR-577 to regulate RAB14 ([@B17]).

HMGA1P6 and HMGA1P7 {#S7.SS6}
-------------------

[@B19] for the first time, reported HMGA1 pseudogenes as candidate proto-oncogenic ceRNAs, including HMGA1P6 and HMGA1P7. HMGA1P7 was found to increase H19 and lgf2 expression by acting as decoy for miR-15, miR-16, miR-214, and miR-761 ([@B14]). [@B15] also showed that HMGA1P7 upregulated miR-483 and miR-675 through a ceRNA mechanism with Egr1.

OCT4-pg4 and OCT4-pg5 {#S7.SS7}
---------------------

Two OCT4-associated pseudogene-derived lncRNAs, OCT4-pg4 and OCT4-pg5, have been reported to act as ceRNAs, thus involving in cancer initiation and progression ([@B96]; [@B3]). OCT4-pg4 promoted growth and tumorigenicity of HCC by growing OCT4 expression through competing for miR-145 ([@B96]). OCT4-pg5 also upregulated OCT4 by sponging miR-145 and thus facilitated cell proliferation of endometrial carcinoma ([@B3]).

PTTG3P {#S7.SS8}
------

Pseudogene PTTG3P was found to be closely related with poor prognosis in HCC and breast cancer. [@B58] suggested that PTTG3P expression positively associated with PTTG1 expression and may function by sponging miR-129-5p, miR-383-5p, and miR-376c-3p. Recently, [@B142] reported that downregulation of PTTG3P promoted apoptosis and decreased proliferation, invasion and migration of HCC cells *via* increasing the expression levels of miR-383 targets, PARP2 and CCND1.

TUSC2P {#S7.SS9}
------

[@B54] indicated that TUSC2P could suppress proliferation, invasion and accelerate apoptosis of esophageal squamous cell carcinoma *in vivo* and *in vitro* through modulating expression of miR-17-5p, miR-520a-3p, miR-608, and miR-661. Besides, it also could serve as a prognostic factor for patients with esophageal squamous cell carcinoma ([@B54]). In addition, TUSC2P was founded to act as a key tumor-inhibitor that could inhibits cell proliferation, migration and invasion in 4T1 and MDA-MB-231 cells ([@B80]). What's more, TUSC2P promotes those functions by binding miR-17, miR-93, miR-299-3p, miR-520a, miR-608, and miR-661 according to the research conducted by [@B80].

ASS1P3 {#S7.SS10}
------

ASS1P3, a pseudogene of ASS1, promoted cell proliferation by functioning as a miRNA decoy for miR-34a-5p in renal cell carcinoma reported by the team of [@B95].

CHIAP2 {#S7.SS11}
------

Pseudogene-derived lncRNA, CHIAP2, suppressed lung adenocarcinoma cell proliferation and invasion by modulation of miR-3614-5p and miR-873-3p-mediated inhibition of NFATC2 and GSK3B ([@B83]).

CYP2A7P {#S7.SS12}
-------

CYP2A7P was discovered to affect expression of its cognate gene CYP2A6 by functioning as a decoy for miR-126 in human liver ([@B68]). However, the effect of CYP2A7P/miR-126/CYP2A6 axis in human cancer containing liver cancer is still not determined.

FOXO3P {#S7.SS13}
------

FOXO3P inhibited tumor growth and angiogenesis by activating FOXO3 activity ([@B120]). By luciferase reporter assay, the authors confirmed that FOXO3P exerted its roles through sponging several miRNAs, including miR-22, miR-136^∗^, miR-138, miR-149^∗^, miR-433, miR-762, miR-3614-5p, and miR-3622b-5p ([@B120]).

GBAP1 {#S7.SS14}
-----

GBA encodes lysosomal glucocerebrosidase and its mutations are associated with Parkinson's disease. Recently, [@B89] demonstrated that GBAP1, a pseudogene of GBA, acted as a ceRNA for GBA by competing with miR-22-3p.

INTS6P1 {#S7.SS15}
-------

INTS6P1, a tumor suppressive pseudogene-derived lncRNA, exerted its roles in HCC by competitively binding to oncogenic miR-17-5p and thus upregulating its cognate gene INTS6 ([@B74]). [@B60] suggested that INTS6 suppressed growth of HCC through Wnt pathway. Taken together, INTS6P1-miR-17-5p-INTS6-Wnt signaling pathway may be a potential therapeutic target in treating HCC.

MSTO2P1 {#S7.SS16}
-------

MSTO2P1 functioned as an oncogenic molecule, including enhanced growth, colony formation, migration and invasion in cervical cancer as mentioned above ([@B48]). The mechanistic investigation revealed that MSTO2P1 exhibited these effects by regulating expression of miR-335 which has been well documented as a potential suppressor of gastric cancer progression ([@B82]).

PDIA3P1 {#S7.SS17}
-------

hMTR4, which promotes RNA degradation, could bind to PDIA3P1, and this interaction was disrupted by Dox treatment ([@B113]). miR-125a/b and miR-124 directly targeted TRAF6, however, PDIA3P1 bound to miR-125a/b and miR-124 and relieved their suppression on TRAF6, thereby causing activation of NF-kB pathway ([@B113]). The novel hMTR4-PDIA3P1-miR-125/miR-124-TRAF6 axis may play a key role in chemoresistance of HCC.

RACGAP1P {#S7.SS18}
--------

[@B98] lately confirmed that pseudogene RACGAP1 is an indispensable molecule for the malignant progression of HCC cells, which was dependent on RACGAP1/Rho/ERK signaling axis.

RP11-424C20.2 {#S7.SS19}
-------------

UHRF1 is a parental gene of pseudogene RP11-424C20.2, it is significantly related with immune infiltration ([@B118]). RP11-424C20.2, a ceRNA, could upregulate UHRF1 expression *via* sponging miR-378a-3p. This axis regulated immune escape of THYM and LIHC by PD-L1 and IFN-gamma-mediated CLTA-4 pathway.

RP11-564D11.3 {#S7.SS20}
-------------

According to bioinformatic analysis, [@B85] found that high expression of RP11-564D11.3 was obviously associated with poor overall survival of multitype cancer patients, such as HCC, mesothelioma, kidney diseases, lung adenocarcinoma, paraganglioma, and pheochromocytoma. Furthermore, seven miRNAs binding with RP11-564D11.3 were predicted, including miR-200b-3p, miR-200a-3p, miR-429, miR-101-3p, miR-9-5p, miR-200c-3p, and miR-141-3p.

RSU1P2 {#S7.SS21}
------

Pseudogene-derived LncRNA, RSU1P2, was founded to be a tumor-promoting molecule in cervical cancer by against let-7a, next regulated N-myc, IGF1R and EphA4 expression ([@B57]).

SEPW1P {#S7.SS22}
------

A recent study reported that piRNA-36712 restrained proliferation, invasion, migration and paclitaxel and doxorubicin resistance of breast cancer, while SEPW1P decreased piRNA-36712 expression by regulating miRNA-7 and miRNA-324, then inhibited P53, p21 and *E*-cadherin, but upregulated Slug ([@B87]).

SUMO1P3 {#S7.SS23}
-------

Recent research found that the expression level of SUMO1P3 was significantly upregulated in non-small cell lung cancer cell lines and cancer tissues. Furthermore, SUMO1P3 promotes NSCLC cells invasion and migration by binding and regulating miR-136 ([@B133]).

WTAPP1 {#S7.SS24}
------

WTAPP1, a molecular decoy for miR-3120-5p, promoted cell migration, invasion and tube formation both *in vitro* and *in vivo* by increasing MMP1 expression and activating PI3K/Akt/mTOR signaling ([@B49]).

Potential Dysregulated Mechanisms of Pseudogene-Derived lncRNAs in Human Cancer {#S8}
===============================================================================

As we mentioned above, a variety of pseudogene-derived lncRNAs have been reported to be frequently dysregulated in various types of human cancer, and a lot attention has been paid to explore the function and action mechanisms of these identified pseudogene-derived lncRNAs in cancer. Only few potential dysregulated mechanisms of pseudogene-derived lncRNA have been reported ([Figure 2](#F2){ref-type="fig"}). Several transcriptional factors are discovered to link to the mis-regulation of pseudogene-derived lncRNAs. For instance, [@B17] revealed that DUXAP8 upregulation in colorectal cancer was induced by STAT3; SIX2 played a positive role in CYP4Z2P expression in breast cancer ([@B137]). Some studies demonstrated that the methylation level of pseudogenes linked to the alteration of pseudogene-derived lncRNAs' expression ([@B42], [@B41]). Hormone and hormone receptor correlated with mis-regulation of pseudogene-derived lncRNAs. For example, [@B59] suggested that KLK31P was stimulated by androgen in prostate cancer; the team of [@B95] found that androgen receptor negatively modulated ASS1P3 expression in renal cell carcinoma. Emerging evidence showed that RNA stability-associated proteins participated in modulation of expression of pseudogene-derived lncRNAs. Human homolog of mRNA transport mutant 4 (hMTR4) led to PDIA3P1 degradation and caused its expression downregulation in HCC ([@B113]). A recent study confirmed that baculovirus mediated expression of PTENP1 in HCC ([@B10]). Besides, exosome also linked to the aberrant expression of pseudogene-derived lncRNA in cancer. [@B141] revealed that PTENP1, transmitted by exosome, significantly suppressed progression of bladder cancer. However, investigations into the mechanisms of pseudogene-derived lncRNAs' upregulation or downregulation remain inadequate. More possible mechanisms causing deregulation of pseudogene-derived lncRNA in cancer need to be explored in the future.

![The potential mechanism responsible for dysregulation of pseudogene-derived lncRNA in cancer.](fcell-08-00085-g002){#F2}

Conclusion and Future Perspectives {#S9}
==================================

Pseudogenes are regarded as non-functional "Genomic evolutional junks" for a long time. During the past few years, researchers have reported that a variety of pseudogenes possess transcribed activities, and some of pseudogene-derived RNA transcripts are validated to play as key regulators in diverse biological processes ([@B108]). Expression and/or function dysregulation of these RNA transcripts account for the occurrence of multiple human disorders, containing cancer ([@B75]; [@B76]). Therefore, performing an all-round overview regarding the expression, function and molecular mechanisms of pseudogene-derived lncRNAs in human cancers may be helpful for developing effective anti-cancer measures.

Benefiting from the advancement of high-throughput sequencing technology and development of bioinformatics analysis, a growing number of pseudogene-derived lncRNAs have been identified, annotated and functionally predicted ([@B37]; [@B28]). As reported, pseudogene-derived lncRNAs are frequently mis-regulated in diverse diseases. But, to date, the role of majority of pseudogene-derived lncRNAs remains unknown. Low expression abundance and high tissue specificity may hamper the interpretation of their functions. The beginning of functional studies for most of pseudogene-derived lncRNAs is usually the cognate genes of pseudogenes. The high homology of pseudogene-derived lncRNAs and transcripts from their cognate genes may be another drag force to impede investigation progression of pseudogene-derived lncRNAs' functions. Of note, the influence of pseudogene-expressed transcripts needs to be excluded when researchers are performing the functional investigations for transcripts from cognate genes.

ceRNA hypothesis, proposed by Salmena et al. (2018) presents a new language among messenger RNAs, lncRNAs and circRNAs by using miRNA response elements. Pseudogene-derived lncRNA transcripts make up a part of lncRNAs. To the best of our knowledge, no studies regarding pseudogene-derived circRNAs have been reported although [@B16] proposed that circRNAs can be retrotranscribed and finally inserted back into the host genome as processed pseudogenes. With the deepening of research, pseudogene-derived circRNA transcripts may be gradually discovered in the future.

To date, most of studies regarding molecular action mechanisms of pseudogene-derived lncRNAs mainly focused on the ceRNA hypothesis by competing shared miRNAs with cognate genes or non-cognate genes ([@B107]; [@B110]). As a subtype of lncRNA, pseudogene-derived lncRNA may also exert its regulatory effects in cancer by other mechanisms, such as binding to transcription factors, producing miRNA/piRNA and encoding proteins ([@B5]; [@B79]). However, these fields are still inadequate. Moreover, most of individual transcripts can't eventually compromise miRNA activity ([@B90]). In the future, more corresponding work should be performed. Of course, the current findings about roles and mechanisms of known pseudogene-derived lncRNAs need to be further precisely validated by basic lab experiments and large clinical trials. Despite all this, finding novel pseudogene-derived lncRNAs as well as circRNAs, identifying their roles in different cancer types and subtypes and developing these pseudogene-derived transcripts-based strategies for diagnosis, therapy and prognosis exhibit very promising in overcoming cancer.
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ceRNA

:   competing endogenous RNA

HBV

:   hepatitis B virus
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:   hepatocellular carcinoma
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:   long non-coding RNA

miRNA

:   microRNA
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ncRNA
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